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Methods: Blood-derived monocytes (BDMs) and monocyte-derived macrophages (MDMs) were
isolated from blood of AD, mild cognitive impairment (MCI) patients, and age-matched healthy con-
trols for molecular and phenotypic comparisons.
Results: The chemokine/chemokine receptor CCL2/CCR2 axis was impaired in BDMs fromAD and
MCI patients, causing a deficit in cell migration. Changes were also observed in MDM-mediated
phagocytosis of Ab fibrils, correlating with alterations in the expression and processing of the trig-
gering receptor expressed on myeloid cells 2 (TREM2). Finally, immune-related microRNAs (miR-
NAs), including miR-155, -154, -200b, -27b, and -128, were found to be differentially expressed in
these cells.
Discussion: This work provides evidence that chemotaxis and phagocytosis, two crucial innate im-
mune functions, are impaired in AD and MCI patients. Correlations with miRNA levels suggest an
epigenetic contribution to systemic immune dysfunction in AD.
 2016 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
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Blood-derived monocytes (BDMs) have been shown to
have a beneficial role in Alzheimer’s disease (AD) mouse
models, associated with a higher ability to clear amyloid
beta (Ab) deposits in the brain [1–3], when compared
with resident microglia. This contribution depends on thedeclared that no conflict of interest exists.
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licenses/by-nc-nd/4.0/).expression of chemokine receptors, such as CCR2, which
mediate BDM migration and infiltration into the brain
parenchyma [4,5] and phagocytosis-related proteins, such
as the new AD risk protein, triggering receptor expressed
on myeloid cells 2 (TREM2) [6]. However, in humans, the
role of BDMs and monocyte-derived macrophages
(MDMs; which directly differentiate from BDMs within tis-
sues) in AD is poorly explored. In vitro, macrophages of AD
patients usually showminimal surface uptake and poor inter-
nalization of Ab [7], although the ability of their blood
monocyte precursors to infiltrate the AD brain is yet poorly
studied.ation. This is an open access article under the CC BY-NC-ND license (http://
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AD pathology in different mouse models. Deficiency in
CCR2 in the Tg2576 and APPSwe/PS1 mice exacerbated
amyloidosis [4,8], whereas transplantation of CCR2-
competent cells into APPSwe/PS1/CCR2
2/2 restored cogni-
tive functions [5]. Moreover, two very recent studies
implicated TREM2 in Ab clearance in vivo, with contradic-
tory results. Although 5XFAD mice deficient in TREM2
showed increased accumulation of Ab and a decrease in
the number of microglia around plaques [9], in the APPPS1
mouse model, the absence of TREM2 resulted in a reduction
of Ab load [10]. In contrast with previous reports that
restricted TREM2 expression to microglia cells [11], the
study in the APPPS1 model hypothesizes that the TREM21
cells found to surround Ab plaques are blood-derived mac-
rophages. Despite these evidences, it is unknown whether,
in the context of human disease, these cells are able to
migrate to the AD brain and phagocyte Ab and how their
function is regulated at the molecular level.
We have recently reported that overexpression of miR-
155 occurs both in M1-activated microglia [12] and in
the brain of 3xTg AD mice [13] and is critical for the
establishment of a chronic inflammatory phenotype. In
this study, we decided to further explore the ability of mi-
croRNAs (miRNAs) to control immune-specific pheno-
types, which hints at a potential use as early biomarkers
of neuroinflammation [14]. For this purpose, we compared
the expression of immune-related miRNAs in AD and mild
cognitive impairment (MCI) patients, with that in healthy
age-matched control subjects. Deregulation of miRNA
expression and functional impairments in chemotaxis and
phagocytosis observed in AD and MCI patients were corre-
lated with the levels of emergent proteins in the realm of
AD research. This work suggests that the deregulation of
specific immune-related miRNAs in AD patients may
contribute to the observed dysfunctions in chemotaxis
and phagocytosis.2. Methods
2.1. Patient selection
Subjects (n 5 124) were recruited at the Neurology
Department, Coimbra University Hospital, 36 age-matched
healthy controls (controls), 52 MCI patients (MCI), and 36
AD patients (AD), and were representative of the Portuguese
Caucasian population. Patients’ diagnostic investigation
comprehended a standard clinical evaluation, routine labora-
tory tests and imaging studies (computed tomography [CT]
orMRI), SPECT, and APOE allele genotyping. TREM2 gen-
otyping for R47Hmutation in exon 2 (associated with higher
AD risk [15]) was performed in all AD and MCI patients
where TREM2 expression was assessed. Positron emission
tomography, cerebrospinal fluid analysis, and genetic
studies were more restricted, although considered in younger
patients.A comprehensive cognitive-functional-psychological
assessment battery was carried out by a team of neuropsy-
chologists, following a standard protocol, and comprising
several tests and scales: (1) cognitive instruments as the
mini-mental state examination (MMSE) [16], the Montreal
Cognitive Assessment (MoCA) [17], the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-Cog) [18],
and a comprehensive neuropsychological battery validated
for the Portuguese population (Battery of Lisbon for the
Assessment of Dementia; [19]) were used to explore mem-
ory and other cognitive domains; (2) the clinical dementia
rating (CDR; [20]) was used for global staging; and (3) the
geriatric depression scale (GDS-30; [21]) was used to
exclude major depression. All MCI patients were classified
at the global CDR staging of 0.5 (no functional impairment)
and were selected according to Albert’s [22] and Petersen’s
criteria [23]. The standard criteria for the diagnosis of AD
patients were the Diagnostic and Statistical Manual of
Mental Disorders–fourth edition and the National Institute
of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders [24]. The AD
group included patients with mild disease (CDR 5 1) or
moderate to severe (CDR 5 2 and 3). The control group
comprised 36 cognitively healthy adults belonging to the
local community (recruited among the patients’ spouses,
hospital or university staff, or their relatives), that were
age, education, and gender matched to the patients. Con-
trols had normal MMSE scores (.24) and were fully auton-
omous in daily life activities (CDR) according to the
information obtained through a general practitioner, and/
or an informant. Moreover, to be eligible for this study, sub-
jects (patients and controls) should be in a stable condition,
without acute significant events or recent/undergoing
changes in medication. Exclusion criteria were (1) signifi-
cant motor, visual or auditory deficits which could influ-
ence the neuropsychological performance; (2) neurologic/
psychiatric conditions other than MCI or AD; (3) CT or
MRI demonstration of significant vascular burden [25];
(4) diagnosis of diabetes, chronic inflammatory, neoplastic
diseases, or prescription of anti-inflammatory drugs; (5)
major depression indicated by a GDS score of 20 or more
points; (6) active smokers; and (7) patients experiencing
uncontrolled hypertension. Informed consent was obtained
from all participants, and the study was conducted in accor-
dancewith the tenets of the Declaration of Helsinki with the
approval of the local ethics committee. Subjects’ informa-
tion/classification was only disclosed in the end of the
study.2.2. Isolation of BDMs
For each study subject, a total of 20 mL of blood was
collected in sterile EDTA-coated tubes. Peripheral blood
mononuclear cells (PBMCs) were isolated by density
gradient centrifugation. BDM isolation was performed
using magnetic separation, employing CD14 MicroBeads
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Supplementary Material. The purity of the CD141 mono-
cytes was determined by flow cytometry, using a mono-
clonal anti-CD14-FITC antibody (Sigma, USA), and was
shown to be more than 96%.
2.3. Flow cytometry analysis
CCR2 and CXCR4 surface expression was analyzed by
flow cytometry using anti-CCR2-PE and -CXCR4-PE anti-
bodies (R&D Systems, USA) and the respective isotype con-
trols, as described in detail in the Supplementary Material.
Each sample was analyzed in a FACScalibur flow cytometer
(BD Biosciences, USA) with the CellQuest Pro software
(BD Biosciences).
2.4. Chemotaxis assay
Cell migration experiments were performed using the
ChemoTx Disposable Chemotaxis System (Neuro Probe,
Inc., USA), as previously described [26] and detailed in
the Supplementary Material. Immediately after isolation,
BDMs were labeled with calcein-AM (Sigma) and seeded
onto a 5-mm pore-membrane. Thirty microliters of chemoat-
tractant were placed in each well of a 96-well multiwell plate
fitted under the membrane: 10 nM CCL2, 12.5 nM CXCL12
(PeproTech, USA), and 5 mM Ab fibrils. After 4 h at 37C,
the calcein fluorescence in each well was determined in a
SpectraMax fluorimeter (lex5 494 nm; lem5 517 nm; Mo-
lecular Devices, USA).
2.5. Preparation of Ab1–42 fibrils and Ab1–42-FAM fibrils
Ab1–42 fibrils were prepared as detailed in the
Supplementary Materials and as previously described [27].
After incubation at 37C for 7 days, the mixture of Ab spe-
cies was centrifuged for 10 minutes at 15,000 g, room tem-
perature, the supernatant was discarded and the pellet,
enriched in Ab fibrils, was resuspended in HAM’s F12 buffer
(pH 7.5) at a final concentration of 50 mM. For the prepara-
tion of Ab1–42-FAM fibrils, 0.1 mg of FAM-labeled Ab1–42
peptide (American Peptide Co., USA) was dissolved in the
same buffer containing 4% dimethyl sulfoxide (DMSO), at
a concentration of 50 mM and then aged for 24 hours at
37C in the dark.
2.6. Primary cultures of MDMs and phagocytosis assay
To promote BDM differentiation into MDMs, BDMs
were plated in RPMI-1640 without fetal bovine serum
(FBS) for 12 hours, and further exposed to 10% FBS and
50 ng/mL M-CSF (Sigma) for 7 days. MDMs were stimu-
lated with 5 mM Ab-FAM fibrils: Ab fibrils 1:5 in RPMI-
1640 10% FBS for 24 hours. LysoTracker Red DND-99
(Life Technologies, USA) was used to stain lysosomes,
whereas the nuclei were labeled with Hoechst 33342, as
described in detail in the Supplementary Material. Confocalimages were acquired in a point scanning confocal micro-
scope Zeiss LSM 510 Meta (Zeiss, Germany), with a !60
oil objective, using the LSM 510 META software.2.7. RNA extraction and quantitative Real-Time
Polymerase Chain Reaction (qRT-PCR)
For a selected number of subjects, a Pick-&-Mix micro-
RNA PCR Panel (Exiqon, Germany), incorporating 90
miRNA and control primers, was performed. Results were
analyzed using the GenEx qPCR analysis software (Exiqon).
The expression of individual miRNAs, found to be differ-
ently expressed between groups, was confirmed by specific
qRT-PCR assays (Exiqon). Messenger RNA (mRNA)
levels of CCR2, CXCR4 and TREM2 genes were also quan-
tified using qRT-PCR as described in detail in the
Supplementary Material. All reactions were performed in
duplicate in a StepOnePlus device (Applied Biosystems,
USA).2.8. Enzyme-linked immunosorbent assay (ELISA) for
soluble TREM2 (sTREM2)
Quantification of sTREM2 in plasma samples was per-
formed by ELISA, as previously described [15] and detailed
in the Supplementary Material. The optical density in each
well was determined at 450 nm, using a SpectraMax Gemini
EM fluorimeter (Molecular Devices).2.9. Statistical analysis
All data are expressed as 6 standard error of the mean
(SEM) and were analyzed for statistical significance using
one-way analysis of variance (ANOVA) followed by Bonfer-
roni’s multiple comparison post hoc test, to compare nor-
mally distributed variables, except for CCR2 and CXCR4
surface expression which were analyzed with two-way AN-
OVA followed by Bonferroni’s post hoc test. To analyze non-
Gaussian data distributions (including sTREM2 quantifica-
tion) and control the effect of potential confounders, such
as gender and age, we log-transformed variables (such as
sTREM2 concentration) to achieve normal distributions.
Differences were considered statistically significant for P
values,.05, .01, and .001, as described in the figure legends.
All tests were two-tailed, and the data were analyzed using
the GraphPad Prism 5 software.3. Results
3.1. The presence of chemokine receptors is reduced at the
cell surface of BDMs from AD and MCI patients
We analyzed the expression levels of CCR2 and CXCR4
in CD141BDMs isolated from patients and control subjects.
A total of 124 subjects divided in three groups were involved
in this study: 36 healthy age-matched subjects (controls), 36
AD patients, and 52 MCI patients. Table 1 summarizes the
Table 1
Characteristics of patient and control study populations
Variable Controls AD MCI
Number of patients (n) 36 36 52
Gender (F/M) (%) 58/42 64/36 46/54
Age (years) 70.3 6 6.6 74.9 6 8.8 73.6 6 8.9
MMSE score .24 15 6 7.6 26.9 6 2.9***
MoCA score 9.8 6 5.8 18.3 6 4.7***
ADAS-cog score — 20.9 6 7.6 9.6 6 4.6***
Stage of disease (CDR) (%)
Mild — 63.9 —
Moderate — 27.8 —
Severe — 8.3 —
APOE genotype ε4, % — 50 37
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impair-
ment; MMSE, mini-mental state examination; MoCA, Montreal Cognitive
Assessment; ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive; CDR, clinical dementia rating; SD, standard deviation; ANOVA,
analysis of variance.
NOTE. Data are expressed as mean6 SD, except for gender (expressed in
percentage of females–F [%] and males–M [%]), stage of disease (CDR; ex-
pressed in percentage of total), and APOE genotype 3 / 34 (expressed in per-
centage of ε4 carries). For MMSE and MoCA, higher scores correspond to
better performance and for the ADAS-cog, higher scores indicate greater
impairment. MoCA and ADAS-cog were only performed in patients with
CDR 1. One-way ANOVAwas used to compare age between groups, fol-
lowed by Tukey’s post hoc test. Two-tailed t test was used to compare
MMSE, MoCA, and ADAS-cog scores, and Fisher’s exact test was used
for APOE genotype. ***P , .001 versus AD.
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three groups presented approximate age and gender
distributions.
We found that the mRNA levels of CCR2 (Fig. 1A) and
CXCR4 (Fig. 1D) were increased by two-fold in BDMs
from AD patients, with respect to both controls and MCI
patients. However, such increase did not translate into an in-
crease of the presence of CCR2 and CXCR4 receptors at the
cell surface. Flow cytometry studies, performed in live cells,
revealed that the percentage of CCR2- BDMs was increased
in both AD andMCI patients, with respect to controls, which
was associated with a decrease in CCR2high populations
(Fig. 1B). A reduction in the CXCR4low population was
also observed in MCI patients, which presented a concomi-
tant increase in CXCR4– cells (Fig. 1E). Fig. 1C and F shows
representative histograms illustrating the distribution of
CCR2 and CXCR4 surface signals in the BDM cell popula-
tion. These results lead us to hypothesize that AD patients
present an impairment in CCR2 mRNA translation. More-
over, although bearing CCR2 and CXCR4 mRNA levels
similar to controls, MCI patients also presented a reduction
in protein levels.3.2. CCL2-driven chemotaxis is impaired in BDM of AD
and MCI patients
To investigate if the lower availability of CCR2 and
CXCR4 at the cell surface of AD and MCI BDMs presented
functional consequences, influencing the ability of thesecells to migrate in response to chemokine gradients, we per-
formed a chemotaxis assay in the presence of CCL2 and
CXCL12, the specific ligands for CCR2 and CXCR4. Imme-
diately after isolation, BDMs were stimulated for 4 hours
with 10 nM CCL2 [28] and 12.5 nM CXCL12 in neuroprobe
chemotaxis chambers (Fig. 2A). As expected, BDMs iso-
lated from AD and MCI patients presented a significant
reduction in cell migration in the presence of CCL2, with
respect to BDMs from controls (Fig. 2C). A similar tendency
was observed in MCI after exposure to CXCL12 (Fig. 2D),
albeit without statistical significance. These results directly
correlated with the increased number of BDMs negative
for CCR2 and CXCR4 observed in AD and MCI (Fig. 1B
and E).
Although previous in vitro studies have suggested that Ab
soluble monomers do not act as a direct chemoattractant for
immune cells [29], it is believed that monocytes can poten-
tially bind to vascular Ab deposits in brain vessels [2].
Therefore, we investigated if other forms of the Ab peptide,
such as Ab fibrils, could act as chemoattractants, by per-
forming a similar chemotaxis experiment using Ab fibrils.
A tendency for reduced cell migration for both MCI and
AD patients was observed (Fig. 2B), suggesting that
BDMs from these patients might be less sensitive to chemo-
taxis signals than controls.3.3. Phagocytosis of Ab fibrils by MDMs is compromised
in both AD and MCI patients
To evaluate phagocytosis efficiency of Ab fibrils by
MDMs, we isolated CD141 BDMs from AD, MCI patients,
and controls and promoted their differentiation into MDMs,
which were incubated with Ab-FAM fibrils for 24 hours
before assessing Ab binding and internalization by confocal
microscopy. LysoTracker was used to label lysosomes and
other acidic compartments and thus determine Ab co-
localization with these organelles. MDMs from controls
were able to bind, internalize, and degrade Ab fibrils very
efficiently because no big Ab aggregates were visible inside
the cells after the 24-hour incubation period (Fig. 3A, left
image). On the other hand, MDMs fromAD patients showed
poor Ab fibril internalization and presented big Ab aggre-
gates associated with the cell membrane (Fig. 3A, middle
image). Moreover, in these patients, intracellular Ab aggre-
gates failed to co-localize with acidic endocytic vesicles. In
contrast to AD patients, MDMs fromMCI showed a massive
uptake of Ab fibrils. Approximately 50% of MCI cells were
able to degrade Ab, whereas the other half presented accu-
mulation of intracellular Ab (Fig. 3A, right image). These
observations translated into a significant increase in intracel-
lular fluorescent signal in MCI, with respect to controls and
AD patients (Fig. 3B). Similar results were observed in a
parallel experiment where internalized unlabeled Ab was
detected by immunocytochemistry (data not shown).
Fig. 1. Presence of surface chemokine receptors CCR2 and CXCR4 is reduced in BDM of AD and MCI patients. The mRNA levels of chemokine receptors
CCR2 (A) and CXCR4 (D) were quantified by qRT-PCR in CD141 BDMs from controls, AD and MCI patients. Results are expressed as mRNA fold change
with respect to the mean of controls and are representative of at least n5 9 per group (one-way ANOVA; **P, .01). *P, .05 and **P, .01 with respect to
controls and #P, .05 with respect to AD patients. CD141 BDM surface expression of CCR2 and CXCR4 proteins was analyzed by flow cytometry. Cell pop-
ulations with negative, low, and high expression of CCR2 (B) and CXCR4 (E) were quantified by histogram analysis. Results are expressed as the percentage of
total cells and are representative of at least n5 7 per group. *P, .05 and **P, .01 with respect to control subjects (two-way ANOVA followed by Bonferroni’s
post hoc test). (C and F) Representative histograms of a control subject, an AD, and an MCI patient for CCR2 and CXCR4 surface expression. Abbreviations:
BDM, blood-derived monocyte; AD, Alzheimer’s disease; MCI, mild cognitive impairment; mRNA, messenger RNA; ANOVA, analysis of variance.
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Rare variants of TREM2 and other new immune-related
genes have been recently associated with higher risk of
developing AD [6,30–32]. In the particular case of
TREM2, reported mutations, including R47H, have been
associated with an impairment in TREM2 processing by
secretases and concomitant shedding of TREM2
ectodomain (sTREM2) [15,33]. Although the R47H
TREM2 mutation was absent in our cohort, the fact that
TREM2 has been implicated in the regulation of
phagocytic activity [15] led us to explore the expression
profile of TREM2 in BDMs and MDMs from AD and
MCI patients. We observed a high increase in TREM2
mRNA expression, in both BDMs and MDMs from MCI
patients, with respect to AD patients (Fig. 4A and B),
and TREM2 expression was only upregulated in MCI
compared with controls in MDMs (Fig. 4B). Interestingly,
sTREM2 levels were elevated in the plasma of AD pa-
tients (Fig. 4C) with respect to both controls and MCI,
suggesting that TREM2 shedding is not directly propor-
tional to TREM2 mRNA expression. Although a slight
decrease in TREM2 mRNA levels was detected in
BDMs from AD patients (Fig. 4A), which could poten-
tially correlate with the observed decrease in Ab phagocy-
tosis, this effect was not present in AD MDMs (Fig. 4B).Nevertheless, the increase in TREM2 expression pre-
sented by MCI patients (Fig. 4B) can help explain the
high Ab uptake observed in these patients.
3.5. Immune-related miRNAs are differentially expressed
in AD and MCI patients
Considering the important role of miRNAs in the con-
trol of immune responses, miRNA deregulation may help
explain, from a mechanistic point of view, changes in
cell-specific phenotypes. In this regard, we investigated
the expression of immune-related miRNAs that, accord-
ing to miRWalk [34], are predicted to bind and regulate
the transduction of proteins implicated in chemotaxis
and phagocytosis. This database uses up to eight different
mathematical algorithms to search for miRNA putative
binding sites in all known mRNAs, mitochondrial genes,
and 10-kb upstream gene flanking regions. Based on this
information, we designed PCR arrays to quantify the
levels of 90 miRNAs (Supplementary Table 1) in
BDMs from 12 AD, MCI patients, and controls. This
study allowed to identify five miRNAs which were differ-
entially expressed in the three experimental groups: miR-
154, -27b, -200b, -128, and -23a. These findings were
confirmed by single qRT-PCR assays in a larger cohort,
using specific primer sets (Fig. 5A–E). Interestingly, all
Fig. 2. CCL2-driven chemotaxis is impaired in AD and MCI BDMs. BDM migration was evaluated using the (A) ChemoTx Disposable Chemotaxis
System (Neuro Probe). CD141 BDMs were labeled with 10 mM of calcein-AM and plated in a chemotaxis membrane. BDMs were stimulated with 5 mM
Ab fibrils (B), 10 nM CCL2 (C), or 12.5 nM CXCL12 (D), placed directly in the chemoattractant chamber. After 4 hours, the calcein signal was
measured by fluorimetry in the wells beneath the membrane. Results are expressed as the number of cells found in the chemoattractant chamber after
a 4-hour stimulation and are representative of at least n 5 9 per group (one-way ANOVA; *P , .05, P 5 .08, and P 5 .1 for CCL2, Ab, and CCL12,
respectively). *P , .05 with respect to control subjects. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; BDMs, blood-derived
monocytes; Ab, amyloid beta; ANOVA, analysis of variance.
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tients, with respect to either controls, MCI patients or
both, which clearly shows that AD patients present
several deficiencies in miRNA networks associated with
inflammation and innate immune response. Because
miR-154 and miR-23a share CCR2 as a predictive target,
whereas miR-27b has been shown to regulate the
CXCL12/CXCR4 axis [35], the observed increase in
these miRNAs may contribute to the impairments
observed in cell migration.
MiR-23a expression was found to inversely correlate with
CCR2 mRNA levels (Fig. 5F) and directly correlate with the
percentage of cells negative for CCR2 (Fig. 5G). Because no
differences in miRNA expression were found between
controls and MCI patients, we can anticipate that all five
miRNAs have potential, as conversion biomarkers, to distin-
guish MCI from AD.
Evaluation of the expression of three miRNAs, miR-
155, miR-145, and miR-124, which serve as signature
markers for the M1, M2a, and M0 activation phenotypes,
respectively (Fig. 5L) [36], did not reveal differences in
miR-124 and miR-145 expression profiles (Fig. 5J and
K) but showcased an increase in miR-155 levels in ADpatients with respect to both controls and MCI (Fig. 5I),
suggesting a tendency toward the M1 phenotype.4. Discussion
In this study, we provide new evidence of the deregulation
of specific immune-related miRNAs in BDMs from AD and
MCI patients, which may have impact in disease pathogen-
esis. According to several miRNA prediction algorithms, at
least two of the identified miRNAs, miR-23a and miR-154,
are able to bind and potentially regulate the 30 untranslated
region (30UTR) of the chemokine receptor CCR2. The
elevated levels of both miR-154 and miR-23a in AD patients
(Fig. 5A and E) can help explain the observed reduction of
CCR2 surface levels because an overexpression of miRNAs
able to bind to the 30UTR of CCR2 mRNA might block its
translation into protein. We hypothesized that the low
CCR2 cell surface expression observed in BDMs from AD
and MCI patients is directly responsible for the impairment
in CCL2-driven chemotaxis detected in these patients
(Fig. 2C). Although studies in mouse models indicate that
the CCR21 BDM population is the only subset of cells
able to efficiently restrict Ab deposition [37], our results
Fig. 3. Internalization of Ab fibrils is compromised in ADMDMs, whereasMCIMDMs present high Ab fibril uptake. CD141BDMswere plated in 8-well ibidi
plates and differentiated into MDMs. MDMs were incubated with 5 mM Ab fibrils (1:5 Ab-FAM fibrils: Ab fibrils) for 24 hours, followed by incubation with
100 nM LysoTracker for 30 minutes at 37C. Phagocytosis of Ab-FAM fibrils was evaluated by confocal microscopy (A) using a Zeiss LSM 510 Meta with a
63x oil objective. The fluorescence intensity inside the cells (B) was quantified using the ImageJ software. For each subject (at least n5 7 per group), six images
were taken and, in each image, the intensity of fluorescence/area of four cells was quantified (one-way ANOVA; ***P , .001). ***P , .001 with respect to
control subjects and #P, .05 with respect to AD patients. Abbreviations: Ab, amyloid beta; AD, Alzheimer’s disease; MCI, mild cognitive impairment; BDMs,
blood-derived monocytes; MDMs, monocyte-derived macrophages; ANOVA, analysis of variance.
J.R. Guedes et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 7-17 13show that, in the context of human disease, CCR2 protein
levels are decreased in AD and MCI BDMs, which may
reduce cell ability to migrate to the brain and clear Ab de-
posits. Despite the heterogeneity of the MCI group, which
reflects the status of AD preclinical stage, the decrease in
CCR2 expression at the cell surface in MCI patients is prom-
inent and can potentially reflect the progression to definitive
dementia. Moreover, because chemokine receptors exert a
scavenging role by binding and removing chemokines
from circulation and tissues [38], the reduction of CCR21
BDMs can contribute to the increased levels of CCL2
observed in the serum of AD patients [39]. Therefore,
although a global increase in CCR2 expression at the cell
surface has been reported in AD PBMCs [40,41], we
provide the missing link regarding CCR2 expression
specifically in BDMs, which does not corroborate the
benefic role observed for monocytes in AD mouse models.Fig. 4. Deregulation of TREM2 mRNA and sTREM2 levels in AD and MCI patie
BDMs and (B)MDMs of controls, AD, andMCI patients. Results are expressed asm
of at least n5 10 (A) and n5 5 (B) per group (one-way ANOVA; *P,.05 and **P
with respect to control subjects and #P, .05, ##P, .01 with respect to AD patients.
ELISA (C). Results are expressed as log sTREM2 with respect to the mean of con
**P , .01). *P , .05 with respect to control subjects, and #P , .05 with respec
myeloid cells 2; AD, Alzheimer’s disease; MCI, mild cognitive impairmen
monocyte-derived macrophages; ELISA, enzyme-linked immunosorbent assay; AConcerning the less studied CXCR4/CXCL12 axis, at
least one study has reported, in parallel with increased cogni-
tive deficits, downregulation of CXCL12 and CXCR4 in
Tg2576 mice [42], which is in line with our findings of a
decrease in CXCR4 surface levels in MCI patients, as well
as reduced migration toward CXCL12 (Fig. 1D and E;
Fig. 2D).
Deficiencies in microglia-mediated Ab phagocytosis
have also been reported in AD [43], suggesting that micro-
glia lose their ability to clear Ab deposits with age and dis-
ease. The similar ontology between monocytes,
macrophages, and microglia [44] and the previously
mentioned observations gave strength to the hypothesis
that circulating monocytes could fulfill the role of microglia,
providing an alternative pathway for Ab clearance [2]. How-
ever, for this process to occur efficiently, both in vascular
deposition sites and the brain parenchyma, blood monocytesnts. TREM2 mRNA expression was quantified by qRT-PCR in (A) CD141
RNA fold changewith respect to themean of controls and are representative
,.01, for TREM2 expression in BDMs and MDMs, respectively). *P, .05
The soluble form of TREM2 (sTREM2)was quantified in plasma samples by
trols and are representative of at least n 5 13 per group (one-way ANOVA
t to AD patients. Abbreviations: TREM2, triggering receptor expressed on
t; BDMs, blood-derived monocytes; mRNA, messenger RNA; MDMs,
NOVA, analysis of variance.
Fig. 5. Immune-related miRNAs are differentially expressed in AD and MCI patients. Immune-related miRNAs (A–E) were quantified in CD141 BDMs of
controls, AD, and MCI patients by qRT-PCR, using individual qRT-PCR assays for each miRNA. Correlations between the levels of miR-23a (fold change
with respect to the mean of controls) in AD patients and (F) mRNA CCR2 fold change or (G) the percentage of cells negative for CCR2 surface expression
are shown. (H) Illustration of the miR-23a binding site in the 30UTR of CCR2 (source: miRNA.org). (I–K)M1-, M0-, andM2a-related miRNAs were quantified
by qRT-PCR in BDMs. Results are expressed as miRNA fold changewith respect to the mean of controls and are representative of at least n5 10 per group (one-
way ANOVA; *P, .05 for miR-154, -200b, and -128 expression and **P, .01 for miR-27b and -155 expression; P5 .166 for miR-23a expression, and ns for
miR-124 and -145). *P , .05 with respect to controls and #P , .05 and ##P , .01 with respect to AD patients. (L) Illustration of M1, M0, and M2a signature
miRNAs. Abbreviations: miRNAs, microRNAs; AD, Alzheimer’s disease; MCI, mild cognitive impairment; BDMs, blood-derived monocytes; mRNA,
messenger RNA; ANOVA, analysis of variance.
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ment, and differentiate into efficient phagocytes. Our results
illustrate an impairment in Ab phagocytosis by AD MDMs,
which was associated with a decrease in Ab internalization
(Fig. 3A) and corroborates previous published results [7].
Therefore, although in ADmouse models their similar coun-
terparts have been shown to contribute to the decrease of Ab
load in the brain, in AD patients, their ability to clear Ab is
clearly compromised. Despite the high Ab internalization
observed in MCI patients (Fig. 3A and B), their cells also
fail to efficiently degrade the peptide, presenting intracel-
lular accumulation of Ab but no co-localization with lyso-
somes or other acidic vesicles (Fig. 3A). This suggests that
the observed impairment in Ab clearance may be multifac-
torial and is not restricted to full-blown AD.
Several of the recently identified AD risk genes have been
directly related with innate immune responses, actin dy-
namics, and clathrin-mediated endocytosis, suggesting that
they may play a role in Ab clearance. In this context, Klein-
berger et al. [15] have recently showed that primary micro-
glia isolated from Trem2 knockout mice present reducedphagocytic ability, whereas inhibition of TREM2 processing
by ADAM10, which resulted in reduced sTREM2 shedding,
was associated with an increase in phagocytosis in BV2
microglia cells [15], probably through the increase of
functional TREM2 at the cell surface.
In what concerns the human disease, only one study
reported elevated TREM2 mRNA levels in peripheral blood
of AD patients with respect to controls [45], although this
study did not include the MCI stage. Moreover, in this study,
TREM2 expression was quantified in RNA extracted from
blood and, therefore, cannot be directly associated with the
mononuclear phagocyte population and with the phagocy-
tosis phenotype. Because the presence of functional
TREM2 at the cell surface was previously associated with
increased phagocytic activity [15], our results led us to hy-
pothesize that the upregulation of TREM2 mRNA expres-
sion observed in MDMs from MCI patients compared with
both controls and AD patients (Fig. 4B) may help explain
the high Ab uptake (Fig. 3B) by MDMs. In addition, the
elevated levels of TREM2 mRNA in BDMs from MCI pa-
tients (Fig. 4A) can constitute evidence of an early
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Interestingly, given the variability in the MCI group, we de-
tected a subgroup within MCI patients that presented similar
TREM2 mRNA levels to those observed in AD BDMs
(Fig. 4A). It would be interesting to perform a translational
evaluation in these patients, to clarify if the shift in TREM2
expression reflects disease progression, because lower levels
of TREM2 mRNA in BDMs from MCI patients (Fig. 4A)
can suggest a more pronounced AD preclinical stage, and
this idea could be explored in the clinic to help disease stag-
ing. We also observed that sTREM2 levels were upregulated
in the plasma of AD patients, with respect to both MCI and
controls (Fig. 4C), which may indicate a reduction in the
availability of functional TREM2 and help explaining the
limited Ab internalization by AD MDMs.
MiR-200b and miR-128, which were also found to be up-
regulated in BDMs from AD patients (Fig. 5C and D), can
also be implicated in the observed impairment in Ab phago-
cytosis. MiR-128 inhibition was shown to improve Ab
degradation in monocytes from AD patients, whereas its up-
regulation led to a decrease in the expression of lysosomal
enzymes [46]. Regarding miR-200b, several databases pre-
dict its binding to the 30UTR of beta-1,4-mannosyl-glyco-
protein 4-beta-N-acetylglucosaminyltransferase (MGAT3).
According to Fiala et al. [47], downregulation of MGAT3
may be related to defective Ab phagocytosis, suggesting a
link between miR-200b upregulation, MGAT3 downregula-
tion, and decreased Ab clearance.
Interestingly, we also found that eight of the new AD sus-
ceptibility genes (CR1, BIN1, PICALM, SORL1, MS4A4A,
CD33, CD2AP, and CLU) [30–32] are predicted targets of at
least one miRNA shown to be differentially expressed
(Supplementary Table 2) and can potentially be regulated
by miR-154, -27b, -200b, -128, and -155. This further
strengthens the idea that miRNA deregulation can be a major
player in sporadic AD. Moreover, the expression of the five
miRNAs found to be upregulated in AD is significantly
different from MCI patients (Fig. 5A–D,I), suggesting that
measuring these miRNAs in the preclinical AD stage could
benefit the clinicians, helping in the staging of dementia.
We have previously studied the role ofmiR-155 in different
neuroinflammatorycontexts andobserved that overexpression
of this miRNA in microglia exposed to LPS [12] or Ab fibrils
[13] is associated with the classical M1 activation phenotype.
In the present study, only miR-155 was differentially ex-
pressed between the three experimental groups. Although
no significant differences were found in the expression of
interleukin 6 and tumor necrosis factor-a (Supplementary
Fig. 1A and B), miR-155 upregulation in AD patients
(Fig. 5I) supports the current belief that BDMs from AD
patients tend toward an M1 phenotype. This finding further
correlates with the observed decrease in Ab phagocytosis,
which has also been associated with the M1 activation state.
Overall, this work point toward a systemic dysfunction of
the innate immune response mechanisms in AD, encompass-
ing two essential immune cell functions, chemotaxis andphagocytosis. Nevertheless, the availability of BDMs ren-
ders these cells promising cellular targets for AD treatment,
and efforts should be made to fully disclosure the events
responsible for the observed impairments. Considering the
potential of miRNAs as biomarkers and molecular targets
of disease, we believe that this study also contributes to
shed light into the molecular mechanisms behind BDM
and MDM dysfunction and opens new miRNA-based ave-
nues for diagnosis and therapeutics in AD.
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1.Systematic review: Systemic inflammation is believed
to play an important role in Alzheimer’s disease (AD),
but is still an unexplored subject, particularly in what
concerns the contribution of mononuclear phagocytes
to amyloid beta (Ab) clearance. We reviewed PubMed
for studies addressing the role of blood phagocytes in
health and disease and found reports suggesting benefic
effects in animal models of AD. However, little informa-
tion is available concerning these cells in the context of
human disease.
2.Interpretation: Our study provides new evidence that
the CCR2/CCL2 axis, crucial for chemotaxis, is deregu-
lated in AD patients. Differences were also detected in
the phagocytosis of the Ab peptide. We correlated these
results with significant changes in the expression
of immune-related microRNAs (miRNAs) and new
AD-associated proteins, such as TREM2.
3.Future directions: Our findings point to important sys-
temic functional impairments in AD patients and sug-
gest caution when translating the knowledge obtained
from AD mouse models to human patients. Future
work includes exploring the link between the identified
miRNAs and the newAD risk proteins frommechanistic
and therapeutic perspectives.
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